NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · IEX Real-Time Price · USD
0.0788
+0.0018 (2.34%)
Apr 26, 2024, 4:00 PM EDT - Market closed
NovaBay Pharmaceuticals Revenue
In the year 2023, NovaBay Pharmaceuticals had annual revenue of $14.73M with 2.24% growth. Revenue in the quarter ending December 31, 2023 was $3.73M with 2.31% year-over-year growth.
Revenue (ttm)
$14.73M
Revenue Growth
+2.24%
P/S Ratio
0.19
Revenue / Employee
$613,583
Employees
24
Market Cap
2.84M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14.73M | 322.00K | 2.24% |
Dec 31, 2022 | 14.40M | 4.20M | 41.16% |
Dec 31, 2021 | 10.20M | 270.00K | 2.72% |
Dec 31, 2020 | 9.93M | 3.34M | 50.54% |
Dec 31, 2019 | 6.60M | -5.91M | -47.24% |
Dec 31, 2018 | 12.51M | -5.72M | -31.39% |
Dec 31, 2017 | 18.23M | 6.33M | 53.23% |
Dec 31, 2016 | 11.90M | 7.52M | 171.56% |
Dec 31, 2015 | 4.38M | 3.33M | 315.65% |
Dec 31, 2014 | 1.05M | -2.42M | -69.69% |
Dec 31, 2013 | 3.48M | -3.47M | -49.95% |
Dec 31, 2012 | 6.95M | -4.07M | -36.95% |
Dec 31, 2011 | 11.02M | 1.27M | 12.97% |
Dec 31, 2010 | 9.75M | -5.93M | -37.81% |
Dec 31, 2009 | 15.68M | 8.96M | 133.32% |
Dec 31, 2008 | 6.72M | 809.00K | 13.68% |
Dec 31, 2007 | 5.91M | 4.38M | 285.71% |
Dec 31, 2006 | 1.53M | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Xylo Technologies | 91.72M |
Dynatronics | 35.18M |
cbdMD | 23.45M |
SCWorx | 3.92M |
INVO Bioscience | 3.02M |
Tenon Medical | 2.93M |
SciSparc | 2.88M |
60 Degrees Pharmaceuticals | 253.57K |
NBY News
- 6 days ago - NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales - Business Wire
- 8 days ago - NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity - Business Wire
- 11 days ago - NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses - Business Wire
- 4 weeks ago - NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results - Business Wire
- 4 weeks ago - NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 - Business Wire
- 6 weeks ago - NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 - Business Wire
- 3 months ago - NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales - Business Wire
- 3 months ago - NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network - Business Wire